AAV vs. Lentivirus vs. LNP: How the Three Leading Gene Therapy Vectors Compare on Payload, Immunogenicity, and Persistence

Selecting the optimal gene therapy vector among AAV, lentivirus, and LNPs requires a strategic trade-off between payload capacity, immunogenicity, and desired expression duration. Each vector platform occupies a distinct niche based on its unique characteristics and therapeutic application.

Juliana Campos

November 1, 2026 · 5 min read

No single gene therapy vector is universally optimal, and the choice among the three leading platforms—adeno-associated virus (AAV), lentivirus, and lipid nanoparticles (LNP)—comes down to a trade-off between efficiency, safety, and therapeutic strategy. AAV delivers small payloads with long-term expression in vivo but is constrained by pre-existing immunity that blocks re-dosing. Lentivirus integrates permanently into the genome, making it the workhorse of ex vivo cell therapy. LNPs carry flexible cargo with low immunogenicity and can be re-dosed, but their expression is transient. Here is how each vector's profile maps to a therapeutic goal.

Introduction to Gene Therapy Vectors

Every gene therapy faces the same first problem: getting genetic material into the right cells, at the right efficiency, without triggering harmful responses. A recent literature review on viral and non-viral vectors highlights delivery to target tissues and immunogenicity as the two challenges that most directly affect safety, durability, and efficacy. Viral vectors achieve high in vivo infection efficiency but can provoke severe immune responses, while non-viral vectors offer low immunogenicity and short expression duration, making them better suited to transient expression—though their infection efficiency still needs improvement. The three vectors examined here dominate current development, and each occupies a distinct niche defined by where it is used, what it can carry, and how long its effect lasts.

Gene Therapy Vector Comparison Matrix

The table below juxtaposes the three vectors against a standardized set of decision-making parameters, drawn from comparative industry data and the published literature review. Use it to locate the intersection of your target application (in vivo versus ex vivo), payload size, and desired expression duration.

Comparison of AAV, Lentivirus, and LNP gene therapy vectors across key decision parameters
Parameter	AAV (Viral)	Lentivirus (Viral)	LNP (Non-Viral)
Primary Use Case	In vivo gene replacement (CNS, eye, liver)	Ex vivo cell therapy (CAR-T, HSCs)	Gene editing (CRISPR/mRNA), vaccines
Cargo Capacity	~4.7 kb (strict limit)	~10 kb (moderate)	Flexible / high
Genetic Persistence	Episomal (long-term in non-dividing cells)	Integrated (permanent in dividing cells)	Transient (ideal for editing)
Immunogenicity	High; neutralizing antibodies prevent re-dosing	Low in practice; use is mostly ex vivo	Low; re-dosable
Key Manufacturing Challenge	Empty/full capsid separation; complex cell culture and purification	Viral stability and titer; shear sensitivity, low yield	Lipid purity and microfluidic fouling; low-to-medium cost

Read horizontally, the table shows why no single vector dominates: AAV's durability comes bundled with a hard payload ceiling and re-dosing barrier, lentivirus's permanence requires an ex vivo workflow, and LNP's flexibility comes at the cost of transient expression.